Skip to content

menu

Rothwell, Figg, Ernst & Manbeck, P.C. logo
HomeAboutContact
Rothwell Figg's

Biosimilars Law Bulletin

RegulatoryLegalNews

NMPA

Subscribe to NMPA via RSS

2019 Ends and 2020 Begins with a Flurry of Biosimilar Activity in East Asian Markets

By Spencer J. Johnson on February 24, 2020
Posted in Regulatory

A white paper released in 2019 by The Biosimilars Forum and Medicines for Europe shows the United States and Europe accounting for more than a combined 80% of sales of biologic medicines, and more than a combined 90% of biosimilars.[1] This, of course, has led to a focus on these markets for the biopharmaceutical…

Blog Editors

Photo of E. Anthony FiggE. Anthony FiggMember
Photo of Joseph A. HyndsJoseph A. HyndsMember
Photo of Jennifer P. NockJennifer P. NockMember
Photo of Aydin H. HarstonAydin H. HarstonMember

About this Blog

Authored and edited by attorneys in Rothwell Figg’s Biologics and Biosimilars Group, Rothwell Figg’s Biosimilars Law Bulletin provides updates, articles, and analyses regarding regulatory issues, legal decisions, and other news related to biologics and biosimilars under the Biologics Price Competition and Innovation Act (BPCIA).

Read More....

Stay Connected

RSS LinkedIn Twitter Facebook
Subscribe to this blog

Topics

Archives

Blog Authors Show/Hide

  • Nicole M. DeAbrantes
  • Rachel M. Echols
  • Michael Ellenberger
  • Aydin H. Harston
  • Mary Mullins
  • Adam Nicolais
  • Jennifer P. Nock
  • Gary Prato
  • Brian Rosenbloom
  • Michael Saunders
  • Alex Shaver
  • Andrew Stewart
  • Andrew J. Storaska
  • Vivian Tian
  • Sheena Wang

Recent Posts

  • Jazz Pharma. v. Avadel CNS Pharma: Federal Circuit Applies a Fact-Specific Approach to the Patent Infringement Safe Harbor
  • How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated May 2, 2025
  • 3 Tips for Avoiding Having to File a Budapest Treaty Declaration When Prosecuting Patent Applications on Biological Materials
  • Federal Circuit: Reissue Patents Get PTE Based on the Original Patent’s Issue Date
  • Federal Circuit Denies Teva’s Request for En Banc Rehearing in Orange Book Patent Dispute

Rothwell Figg Blogs

  • Privacy Zone
  • PTAB Law Blog
  • RF EMerge
  • Trademark Opposition Lawyer
Rothwell, Figg, Ernst & Manbeck, P.C.
Washington, DC
901 New York Avenue, NW
Suite 900 East
Washington, DC 20001
202.783.6040
BiosimilarsIPeditors@rothwellfigg.com
Boston
10 Derne Street
Suite 302
Boston, MA 02114
617.312.3101
BiosimilarsIPeditors@rothwellfigg.com
New York
80 South Highland Ave
Ossining, NY 10562
914.941.5668
BiosimilarsIPeditors@rothwellfigg.com
RSS LinkedIn Twitter Facebook
Privacy PolicyDisclaimer

About Our Firm

To learn more about our firm and other practice areas, visit www.rothwellfigg.com.

Copyright © 2025, Rothwell, Figg, Ernst & Manbeck, P.C.. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo